AmpliPhi swallows SPS to expand bacteriophage breadth
This article was originally published in Scrip
Executive Summary
Two companies specialising in bacteriophage technologies are to join forces as AmpliPhi, which has operations in the UK and US, prepares to acquire Sydney, Australia-based Special Phage Services (SPS). The all-share transaction will create "the world's leading anti-infective company focused on bacteriophage-based therapies", they claim.